As part of the settlement, "Cipla would discontinue all use of the DA Double Advantage trademark (in the US and on a global basis). Cipla will also stop use of the trademark Advance for a companion animal product; refrain from manufacturing any product with the same formula as Bayer's patented Advantix and K9 Advantix II (US) products during the remaining term of those patents; and disgorge its total profits from the sale of DA Double Advantage, in excess of $100,000," Bayer said.